Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, ...

No-moat Myriad Genetics reported robust second-quarter results that surpassed our expectations. The solid revenue growth indicates strong demand for the company's core offerings, prompting ...

Analysts have set 12-month price targets for Myriad Genetics, revealing an average target of $24.5, a high estimate of $32.00, and a low estimate of $21.00.

Myriad Genetics Inc <MYGN.O> said on Thursday that Denmark's H Lundbeck A/S <LUN.CO> will acquire European rights to its experimental Alzheimer's disease drug Flurizan, but the deal will increase ...